Published in Proc Natl Acad Sci U S A on July 11, 2007
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature (2014) 3.15
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer (2012) 2.20
The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res (2008) 2.19
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer (2010) 1.80
Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature (2016) 1.63
Microtubule dynamics as a target in oncology. Cancer Treat Rev (2008) 1.50
Breast cancer in young women and its impact on reproductive function. Hum Reprod Update (2009) 1.40
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol (2010) 1.35
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech (2009) 1.34
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med (2013) 1.26
Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012) 1.24
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene (2011) 1.20
Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells. Mol Cancer Res (2010) 1.16
Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer (2011) 1.10
Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas (2010) 1.08
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 1.05
Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Res (2008) 1.05
A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res (2009) 1.04
Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med (2015) 1.03
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res (2014) 1.03
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol (2011) 1.02
Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. PLoS One (2009) 1.00
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J Cancer Ther Res (2014) 0.99
Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. Cell (2016) 0.98
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet (2011) 0.96
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist (2013) 0.95
Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer (2009) 0.95
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest (2016) 0.94
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93
Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J (2016) 0.92
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci U S A (2015) 0.90
The use of GEM models for experimental cancer therapeutics. Dis Model Mech (2008) 0.89
Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. Cell Cycle (2010) 0.87
It's all in the details: methods in breast development and cancer. Breast Cancer Res (2009) 0.87
Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer (2017) 0.87
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. Am J Pathol (2011) 0.86
BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. Genes Dev (2012) 0.86
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Dis (2010) 0.85
Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem (2009) 0.84
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep (2016) 0.83
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One (2012) 0.82
Personalized targeted therapy for esophageal squamous cell carcinoma. World J Gastroenterol (2015) 0.82
Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. Mol Cell Proteomics (2013) 0.81
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. Oncologist (2016) 0.80
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion. Proc Natl Acad Sci U S A (2016) 0.80
Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. J Transl Med (2015) 0.79
Monitoring of tumor response to Cisplatin using optical spectroscopy. Transl Oncol (2014) 0.79
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. PLoS One (2014) 0.78
In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech (2017) 0.78
Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med (2016) 0.77
Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration. Oncotarget (2016) 0.77
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. Eur J Nucl Med Mol Imaging (2008) 0.77
Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells. Br J Pharmacol (2013) 0.76
Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech (2015) 0.76
Differential remodeling of extracellular matrices by breast cancer initiating cells. J Biophotonics (2015) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget (2017) 0.75
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK). Oncotarget (2017) 0.75
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res (2002) 40.03
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet (2001) 9.55
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J (1999) 9.00
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
Rosetta error model for gene expression analysis. Bioinformatics (2006) 4.67
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem (2000) 4.49
The role of apoptosis in cancer development and treatment response. Nat Rev Cancer (2005) 4.19
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev (1999) 4.13
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2006) 3.04
If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat (2001) 2.97
Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother (2004) 2.72
Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med (2000) 2.59
Apoptosis is critical for drug response in vivo. Drug Resist Updat (2001) 2.37
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer (2003) 2.26
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther (2003) 1.41
Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer--a prospective clinical study. World J Surg Oncol (2005) 1.34
Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol (1990) 1.27
Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist Updat (2001) 1.22
Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets (2006) 1.16
Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol (1997) 1.04
DNA damage responses and chemosensitivity in the E mu-myc mouse lymphoma model. Cold Spring Harb Symp Quant Biol (2000) 1.01
Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA. Nucleic Acids Res (2005) 0.97
Does cancer therapy trigger cell suicide? Science (1999) 0.92
Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther (2003) 0.92
Apaf-1 expression in malignant melanoma. Cell Death Differ (2006) 0.88
CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer (2006) 0.88
Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging. Eur J Nucl Med Mol Imaging (2002) 0.86
An ethanol-acetic acid-formol saline fixative for routine use with special application to the fixation of non-perfused rat lung. Lab Anim (1984) 0.86
Cancer cell death by programmed necrosis? Drug Resist Updat (2005) 0.85
Differential recognition of mdr1a and mdr1b gene products in multidrug resistant mouse tumour cell lines by different monoclonal antibodies. Br J Cancer (1992) 0.83
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (2010) 5.02
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol (2011) 4.18
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell (2007) 3.14
Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res (2003) 3.02
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood (2009) 2.49
Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res (2005) 2.41
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 2.35
Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med (2006) 2.33
Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol (2004) 2.31
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer (2012) 2.20
The protein that binds to DNA base J in trypanosomatids has features of a thymidine hydroxylase. Nucleic Acids Res (2007) 2.19
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics (2007) 2.15
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet (2007) 2.14
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc (2009) 1.95
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2003) 1.90
Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population. Atherosclerosis (2009) 1.88
Mutagenic insertion and chromosome engineering resource (MICER). Nat Genet (2004) 1.88
A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Respir Crit Care Med (2005) 1.82
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer (2009) 1.80
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain (2008) 1.77
qpure: A tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS One (2012) 1.77
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol (2003) 1.73
Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res (2003) 1.68
Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques (2007) 1.66
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J (2008) 1.62
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol (2011) 1.61
How do real tumors become resistant to cisplatin? Cell Cycle (2008) 1.60
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol (2006) 1.59
Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis (2011) 1.58
Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch (2006) 1.58
A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification. J Exp Med (2007) 1.57
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
[Open letter to the members of the GOLD committee]. Rev Mal Respir (2010) 1.57
Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. J Pathol (2012) 1.57
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. J Nucl Med (2012) 1.53
Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res (2008) 1.52
Inflammation, proteases and cancer. Eur J Cancer (2006) 1.52
Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res (2007) 1.48
Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem (2004) 1.46
Glucosylated hydroxymethyluracil, DNA base J, prevents transcriptional readthrough in Leishmania. Cell (2012) 1.46
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol (2008) 1.45
Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene (2004) 1.44
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol (2010) 1.44
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat (2006) 1.40
Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle (2008) 1.37
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
What makes tumors multidrug resistant? Cell Cycle (2007) 1.34
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol (2005) 1.32
A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. Genome Res (2004) 1.32
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res (2006) 1.31
ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proc Natl Acad Sci U S A (2013) 1.31
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Deletion and duplication screening in the DMD gene using MLPA. Eur J Hum Genet (2005) 1.30
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30